We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · September 06, 2021

Hyper-CVAD Plus Ofatumumab Versus Hyper-CVAD Plus Rituximab as Frontline Therapy in Adults With Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia

Cancer

 

Additional Info

Cancer
Hyper-CVAD Plus Ofatumumab Versus Hyper-CVAD Plus Rituximab as Frontline Therapy in Adults With Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Propensity Score Analysis
Cancer 2021 Sep 15;127(18)3381-3389, K Sasaki, HM Kantarjian, K Morita, NJ Short, M Konopleva, N Jain, F Ravandi, G Garcia-Manero, S Wang, JD Khoury, JL Jorgensen, RE Champlin, IF Khouri, P Kebriaei, HM Schroeder, M Khouri, R Garris, K Takahashi, SM O'Brien, EJ Jabbour

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading